Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats Lennox-Gastaut syndrome (petit mal variant), akinetic, and myoclonic seizures. Sold as Klonopin, Klonopin Rapidly Disintegrating. Every FDA application for this active ingredient: 2 branded and 17 generic.
As of Nov 14, 2026, FDA lists 19 applications for Clonazepam (sold as Klonopin, Klonopin Rapidly Disintegrating), first approved Jun 4, 1975, with 1 new use approved and 0 published complete response letters.
First approved: Jun 4, 1975
Applications: 19
New uses approved: 1
Complete response letters: 0
Medicare spending, 2025: $77.1M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Teva
Sandoz
Roche
Aurobindo Pharma USA
Sun Pharm Inds Inc
Accord Hlthcare
Alembic